Q2 2026 results show a narrower net loss and extended cash runway into Q1 2027
ELTX sits 17% above its 52-week low of $2.66 on light trading volume (0.1× avg).
Summary
Q2 2026 results show a narrower net loss and cash runway into Q1 2027, while the ELI-002 7P clinical program advances with new Phase 1 trials.
Key Events · Earnings and Guidance · ELTX
-
Q2 2026 Financial Results
The net loss narrowed to $8.2 million from $10.6 million in Q2 2025. R&D expense was $6.8 million and G&A expense was $3.6 million.
-
Cash Runway Extended
Cash and cash equivalents of $23.5 million as of June 30, 2026, are expected to support operations into Q1 2027.
-
ATM Program Proceeds
Net proceeds of $16.6 million were raised in Q2 2026 through the ATM program, bringing year-to-date ATM net proceeds to approximately $24.4 million.
-
New Phase 1 Trials
An investigator-initiated Phase 1 neoadjuvant trial led by Memorial Sloan Kettering has been activated; a Phase 1 combination study is planned for Q4 2026.
Analysis · ELTX · Life Sciences
Second quarter 2026 financial results revealed a net loss of $8.2 million, an improvement from $10.6 million a year earlier. Cash and cash equivalents stood at $23.5 million as of June 30, 2026, and management expects this to fund operations into the first quarter of 2027. The company also announced the activation of a Memorial Sloan Kettering-led Phase 1 neoadjuvant trial and plans to initiate a Phase 1 combination study in Q4 2026. These updates provide clarity on the company's financial position and clinical development path following the Phase 2 AMPLIFY-7P trial miss in June.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELTX was trading at $3.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.9M. The 52-week trading range was $2.66 to $16.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.